Clinical trials: Renal Transplant Recipients
Cardiovascular Disease, Cardiovascular Outcomes
Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
The overall goal of this study is to improve cardiovascular outcomes in transplant recipients. The current standard immunosuppressive regimen in kidney transplant recipients depends on a higher exposure to the Calcineurin…
- Conditions
- Cardiovascular Disease, Cardiovascular Outcomes, Kidney Transplant Recipients, Kidney Transplantation
- Trial name
- COBACAM (NCT02058875)
- Testing
- Myfortic®, Neoral®, Cellcept®
- Where
- 2 sites in Canada
- Sponsor
- University of Saskatchewan
Kidney Transplant, Chronic Kidney Disease
Empagliflozin Treatment in Kidney Transplant Recipients
Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging.
- Trial name
- SEKTR (NCT06013865)
- Testing
- Empagliflozin
- Where
- 5 sites in United States
- Volunteers
- 264 people
- Sponsor
- VA Office of Research and Development
Renal Transplantation
Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients
This multicentre, prospective, randomized, open-label study will compare the safety and efficacy of mycophenolate mofetil with delayed introduction of sirolimus and discontinuation of cyclosporine, with those of mycophenolate…
- Trial name
- NCT02686619
- Testing
- Cyclosporine, Daclizumab, Mycophenoate Mofetil
- Where
- 17 sites in France
- Volunteers
- 237 people
- Sponsor
- Hoffmann-La Roche
Planned Kidney Transplantation
Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation
Calcineurin inhibitors, such as cyclosporine and tacrolimus, have improved allograft survival in kidney organ transplantation. Indeed, they have reduced the incidence of acute rejection episodes of cadaveric allograft recipients.
- Trial name
- NCT01706471
- Testing
- Everolimus + Low dose CsA +PD, Myfortic+ Standard CsA + PD
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Hypertension Secondary to Kidney Transplant
Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients
The proposed study investigated the effect of chronotherapeutic alteration of anti-hypertensive medication on nocturnal hypertension and end-organ injury in pediatric renal transplant recipients who are non-dippers.
- Trial name
- NCT01007994
- Testing
- New Medication: Enalapril, Isradipine, Propranolol
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Northwell Health
Chronic Kidney Disease, Cardiovascular Disease
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Death
- Trial name
- FAVORIT (NCT00064753)
- Testing
- High Dose Multivitamin, Low Dose Multivitamin
- Where
- 30 sites in United States, Brazil and 1 more
- Volunteers
- 4,110 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Transplant Dysfunction
Safety and Effect of Low-Energy Extracorporeal Shockwave Therapy (ESWT) on the Renal Allograft in Transplant Recipients.
The aim is to investigate the safety and potential effect of Low-energy Shockwave Therapy (ESWT) on the transplanted kidney. The treatment consist of ESWT two times a week for three weeks, six treatments in total.
- Trial name
- NCT03602807
- Testing
- Extracorporeal Shockwave Therapy
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Odense University Hospital
Kidney Replacement
Pilot of IMPACT Intervention at the University of New Mexico
Kidney transplant recipients (KTR) are at greater risk of weight gain, diabetes and cardiovascular events post-transplant; but medications are limited in their effectiveness, and patients may face contraindications and unwanted…
- Trial name
- IMPACT (NCT04166994)
- Testing
- Exercise and diet, No Intervention: Usual Care
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of New Mexico
Renal Transplant Recipients
Sexual Function in Male Renal Transplant Patients
Sexual dysfunction is common in male patients with chronic renal failure on dialysis and after renal trasnplantation. Multiple factors play a role in this important clinical problem.
- Trial name
- NCT00271830
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Montefiore Medical Center
Transplant;Failure,Kidney
Clinical Pharmacy Guided Patient Counselling and Adherence Support on Renal Transplant Recipients
As a result of the shortage of donor organs and the close relationship between allograft or even life loss and non-adherence after kidney transplantation, improvement of patient adherence appears essential.
- Trial name
- NCT04715412
- Testing
- patient counseling and adherence support
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Future University in Egypt
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Renal Transplantation
ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
The study is designed to evaluate whether the initiation of everolimus together with the reduction or discontinuation of calcineurin inhibitors (CNIs) will improve graft function in the maintenance of renal transplant recipients…
- Trial name
- NCT00170846
- Testing
- Everolimus (RAD001), Calcineurin Inhibitors (CNI), Mycophenolate acid (MPA)/Azathioprine (AZA)
- Where
- Switzerland
- Volunteers
- 394 people
- Sponsor
- Novartis Pharmaceuticals
Renal Disease
Causes of Mortality in Kidney Transplant Recipients
The causes of mortality in kidney transplant patients and the risk factors for mortality have been widely published. However, there is a high variability according to geographical areas and time.
- Trial name
- Paradigme (NCT05529186)
- Where
- France
- Volunteers
- 7,000 people
- Sponsor
- University Hospital, Strasbourg, France
CMV Disease
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients.
- Trial name
- NCT03443869
- Testing
- Letermovir, Valganciclovir, Acyclovir (ACV)
- Where
- 94 sites in United States, Argentina and 14 more
- Volunteers
- 601 people
- Sponsor
- Merck Sharp & Dohme LLC
Transplantation
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients
Assessment of the safety and the efficacy of a tacrolimus modified release (MR4) based immunosuppressive regimen in stable kidney transplant subjects converted on a 1:1 (mg:mg) basis from a Prograf® based immunosuppressive…
- Trial name
- NCT00384137
- Testing
- Tacrolimus
- Where
- 13 sites in France, Germany and 4 more
- Volunteers
- 128 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplantation
Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China
The primary objective of this study is to evaluate graft survival and recipient survival among kidney transplant recipients in China, and also to analyze possible factors related to patient and graft survival.
- Trial name
- REACH (NCT01796639)
- Where
- 18 sites in China
- Volunteers
- 1,500 people
- Sponsor
- Novartis
Diabetes Mellitus, Adult-Onset
Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the basis of modern immunosuppression.
- Trial name
- 01-DMPT (NCT01002339)
- Testing
- Tacrolimus with rapid steroid withdrawal, Tacrolimus with steroids minimization, CsA with steroid minimization
- Where
- 10 sites in Spain
- Volunteers
- 134 people
- Sponsor
- Armando Torres Ramírez
Kidney Transplant Rejection
Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients
This is a randomized, open-label, controlled clinical trial designed to compare clinical outcomes after kidney transplantation using extended-release tacrolimus (Envarsus XR) versus immediate tacrolimus among highly-sensitized…
- Trial name
- NCT04225988
- Testing
- Extended-release tacrolimus, Immediate-release tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Medication Adherence
Medication Adherence in Kidney Transplant
Aims and Objective: The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
- Trial name
- NCT06004102
- Testing
- reminder text message
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Akdeniz University Hospital
Renal Transplantation
Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
The aim of the study is to assess the short-term benefit of the combination of basiliximab, EC-MPS and cyclosporine microemulsion with C2 monitoring on the prophylaxis of acute rejection in a population of de novo renal…
- Trial name
- NCT00154232
- Testing
- Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.